An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new provider called T·Time is offering compounded injections that mix GLP-1 and GIP hormones, and they’re selling them directly to customers for a flat cash price. The story is that these are being made outside of brand-name drug manufacturing — compounded by a pharmacy — and are available through this cash-pay model rather than through traditional prescription coverage or branded clinics. GLP-1 and GIP are types of natural hormones your gut releases after you eat. They help control appetite and blood sugar by sending signals to your brain and pancreas. Prescription drugs like Ozempic or Wegovy mimic GLP-1 to help with diabetes and weight loss. Compounded versions are custom-made mixes created by a pharmacy, not the original branded drugs. That means the ingredients and doses can be different from what the big manufacturers produce. The announcement doesn’t present a clinical trial or new research showing these compounded shots work as well as, or are as safe as, the brand-name medicines. It’s a business launch: a pharmacy offering an alternative product and a predictable flat price for people who pay out of pocket. There’s no mention of large human studies backing this specific compounded combination, no safety testing results provided, and no comparison numbers showing how much weight or blood sugar change to expect. So the actual evidence for effectiveness and safety, as reported, is limited or not described. This matters because GLP-1–based drugs are already in high demand for diabetes and weight management, and cost plus access are major issues. A flat cash price and compounded options could make these hormones more available for some people who can’t get or don’t want branded prescriptions or who lack insurance coverage. For consumers, it’s an option worth noticing if you’re managing weight or blood sugar and are exploring treatment choices outside standard branded products. There are important caveats and risks. Compounded products are not reviewed or approved by regulators in the same way brand-name drugs are, so their exact potency, purity, and safety profile can vary. Side effects known for GLP-1 drugs include nausea, stomach upset, and more serious but rarer concerns; mixing hormones or changing doses adds uncertainty. People with certain medical conditions, or who are pregnant, breastfeeding, or taking other medications, should not try new injections without a doctor’s advice. The announcement doesn’t say these compounded injections have regulatory approval or robust clinical testing. Bottom line: T·Time is selling cash-pay compounded GLP-1/GIP injections as a lower-complexity pricing option, but the public report doesn’t provide trial data or regulatory clearance, so anyone interested should ask a clinician and check product testing and legal status before considering use.
Source: The Manila Times